SCHEMBL3147735

SCHEMBL3147735

CCOC(=O)CCNC(=O)c1ccc(S(=O)(=O)N(Oc2ccc(Cl)cc2Cl)c2ccccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
KMT2A Q03164 3/20 0.42
HPGD P15428 1/20 0.42
TP53 P04637 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
CXCR3 P49682 1/20 0.40
GPR27 Q9NS67 1/20 0.40
GAA P10253 1/20 0.40
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40
APH1B Q8WW43 1/20 0.40
NCSTN Q92542 1/20 0.40
APH1A Q96BI3 1/20 0.40
PSENEN Q9NZ42 1/20 0.40
MEN1 O00255 1/20 0.40
HSP90AA1 P07900 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3053654 0.91 NPC1 (0.43) SMN1; SMN2KMT2AHPGDTP53NPC1
SCHEMBL3153189 0.89 CA1 (0.46) MCHR1SMN1; SMN2KMT2AHPGDNPC1
SCHEMBL3153923 0.86 SMN1; SMN2 (0.58) MCHR1SMN1; SMN2KMT2AHPGDNPC1
SCHEMBL3154165 0.86 CYP1A2 (0.47) MCHR1SMN1; SMN2KMT2AHPGDNPC1
Hydrochloric Acid SCHEMBL3157034 0.85 KMT2A (0.48) MCHR1SMN1; SMN2KMT2AHPGDNPC1
SCHEMBL3050363 0.84 CA1 (0.46) MCHR1SMN1; SMN2KMT2AHPGDCXCR3
SCHEMBL3260542 0.83 MCHR1 (0.43) MCHR1SMN1; SMN2KMT2AHPGDTP53
SCHEMBL3050632 0.83 GLA (0.41) SMN1; SMN2KMT2AHPGDTP53NPC1
SCHEMBL3052653 0.83 MAPT (0.44) SMN1; SMN2HPGDNPC1RAB9AGAA
SCHEMBL3137635 0.82 GPR27 (0.47) SMN1; SMN2KMT2AHPGDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074083-B1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-06-19 EP disclosed
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-03-25 US disclosed
EP-2074083-A1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-07-01 EP disclosed
WO-2008050168-A1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, TRPV1 MCHR1 585/4885SMN1; SMN2 3719/4885KMT2A 3835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.